Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre, shared a post on X:
“OMET trial (GORTEC 2014-04) in oligometastatic HNSCC.
N=69, SABR alone vs SABR + chemo + cetuximab.
Key finding:
- Similar 1-year OS without QoL (SABR 55.2% vs chemo-SABR 53.3%).
- SABR alone had toxicity and QoL impact.
- Gr 3–4 tox: 8.8% (SABR alone) vs 60%.
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.
Authors: Juliette Thariat, et al.
Phase II randomized design:
- 1–3 oligometastases, mostly lung.
- Median OS ~42 mo both arms.
- QoL deterioration (median drop):
– SABR: 16.7 patients.
– Chemo-SABR: 50 patients.
QoL assessed with EORTC QLQ-C30.”
Toxicity snapshot:
Grade ≥3 toxicity:
- 60% with chemo vs 8.8% with SABR-only.
- No grade 5 events.
- Chemo toxicities: anemia, nausea, mucositis, hypomagnesemia, etc.
QoL declines closely linked to non-haem grade ≥3 toxicities.”
Bottom line for clinicians:
In select patients with oligometastatic HNSCC, SABR alone offers comparable survival with toxicity and better QoL.
Repeated SABR feasible at relapse SABR-only arm also shown to be cost-efficient.
Full paper.
Sue Yom–ASTRO upcoming podcast for APRIL 2025.”
